Peptidomimetics are structural analogs of peptides or proteins that mimic their biological activities. They are designed to overcome limitations associated with peptides, such as poor stability and bioavailability by preserving or enhancing their functions. Peptidomimetic development involves the design and synthesis of molecules that mimic three-dimensional...
Alfa Cytology has announced cancer diagnostic biomarker development services to enhance precision in oncology research.
Alfa Cytology, a pioneering biotech firm comprising an interdisciplinary team of scientists, bioinformaticians, and oncologists, has recently introduced its cancer diagnostic biomarker development services to advance personalized...
Cancer is a daunting diagnosis; however, the rapid advancements in oncology are continuously perfecting patient outcomes and quality of life. Among the groundbreaking developments, cancer vaccines are a promising frontier1. These vaccines are transforming how we approach cancer treatment, leveraging the body's immune system to fight malignancies more effectively. To grasp how cancer...
Brain tumors can be broadly categorized into primary and secondary (or metastatic) tumors. Primary tumors originate in the brain1, while secondary tumors spread from other body parts. Treatment options traditionally include surgery, radiation therapy, and chemotherapy. However, these approaches can be invasive and have severe side effects.
The battle against brain tumors is...
The development of monoclonal antibodies (mAbs) has completely transformed the field of medicine, providing targeted antidotes against a wide range of diseases, including cancer, autoimmune and infectious diseases. These therapeutic antibodies aim to specifically target antigens on the surface of cells and bind to them, leading to acidic reactions that result in the destruction of target...
Alfa Cytology has unveiled its breast cancer model construction services in cancer therapy.
Alfa Cytology, known as an outstanding biotech company with rich experiences in tumor research, has recently announced breast cancer model construction services, aiming to support researchers in reasoning mechanisms and characteristics of breast tumors.
Breast...
Alfa Cytology has announced its small molecule drug development to advance preclinical cancer research.
Alfa Cytology, a comprehensive biotech company specializing in cancer research, has recently announced the cancer small molecule drug development services. The services tend to accelerate the discovery and optimization of molecule drugs with a strict quality control system....
Alfa Cytology has announced tumor models customization service for pancreatic cancer research.
Alfa Cytology, a biotech company specializing in cancer research, has recently unveiled the service on pancreatic cancer tumor model customization to dig into the generation and development of pancreatic cancer and correspondingly provides customized plans for study.
Pancreatic...
Ongoing research and inventions in the field of oncology focus on the development of small molecule drug therapies for use in brain tumor resection. Small molecule drugs are being developed to target and effectively treat brain tumors to improve therapeutic outcomes. Small particles containing compounds that can enter cells and interact with specific targets to inhibit or modulate...
Alfa Cytology has announced pancreatic cancer vaccine development services to improve the efficacy and safety of related vaccines.
Alfa Cytology, a biotech company composed of scientists, bioinformatics, and oncologists, has recently announced its pancreatic cancer vaccine development services to provide further strategies for cancer therapy research.
Compared to...
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian